Compare BN & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BN | ZTS |
|---|---|---|
| Founded | 1997 | 1952 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6B | 66.2B |
| IPO Year | N/A | 2013 |
| Metric | BN | ZTS |
|---|---|---|
| Price | $45.61 | $118.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $42.41 | ★ $174.60 |
| AVG Volume (30 Days) | 4.8M | ★ 5.0M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | 0.53% | ★ 1.69% |
| EPS Growth | 7.66 | ★ 11.64 |
| EPS | 0.35 | ★ 5.94 |
| Revenue | ★ $76,933,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | N/A | $3.11 |
| Revenue Next Year | $68.39 | $5.14 |
| P/E Ratio | $125.71 | ★ $19.99 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $29.07 | $115.25 |
| 52 Week High | $49.47 | $181.85 |
| Indicator | BN | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 38.87 |
| Support Level | $45.78 | $115.59 |
| Resistance Level | $47.81 | $129.58 |
| Average True Range (ATR) | 0.96 | 3.06 |
| MACD | 0.33 | 0.17 |
| Stochastic Oscillator | 39.58 | 23.09 |
Brookfield Corp is an investment firm focused on building long-term wealth for institutions and individuals. It has seven operating segments: Asset Management, Wealth Solutions, Renewable Power and Transition, Infrastructure, Private Equity, Real Estate and Corporate Activities. It invests in real assets that form the backbone of the economy to deliver risk-adjusted returns to stakeholders. The company generates the majority of its revenue from Asset Management. It has a geographic presence in the UK, the United States, Australia, Canada, Brazil, India, Colombia, Germany, Other Europe, Other Asia, and other countries.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.